Role of acid milieu in the gastroprotective and ulcer-healing activity of sucralfate.
Sucralfate prevents the formation of acute gastric lesions induced by various ulcerogens and enhances the healing of chronic gastroduodenal ulcerations, but the mechanism of these effects has not been fully explained. This study was designed to determine the importance of intragastric pH in the sucralfate-induced gastroprotection against 100% ethanol, acidified aspirin, taurocholate, or stress, and in the healing of chronic gastroduodenal ulcerations induced by acetic acid. Sucralfate acidified to pH 2.0 showed significantly stronger protective activity against all four irritants, its protective potency against 100% ethanol being about eight times greater and the duration of the protection about four times longer than those obtained with sucralfate at its pH of 5.0. Pretreatment with indomethacin to suppress mucosal generation of prostaglandin or the removal of salivary glands to eliminate the endogenous source of epidermal growth factor failed to affect sucralfate-induced gastroprotection. In contrast, the rate of healing of chronic gastric ulcerations was significantly delayed by indomethacin or sialoadenectomy; but sucralfate enhanced the healing, and a marked inhibition of gastric acid secretion by ranitidine did not eliminate this enhancement. We conclude that the protective activity of sucralfate depends on the presence of acid milieu in the stomach, but that the ulcer-healing effects of this drug occur even after a marked inhibition of gastric acid secretion.
Konturek
S J
SJ
Institute of Physiology, Academy of Medicine, Krakow, Poland.
Brzozowski
T
T
Drozdowicz
D
D
Garlicki
J
J
Majka
J
J
Pytko-Polonczyk
J
J
D000818:Animals; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004815:Epidermal Growth Factor / Q000737:chemistry; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000737:chemistry / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D007213:Indomethacin / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D011458:Prostaglandins E / Q000096:biosynthesis; D011899:Ranitidine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012469:Salivary Glands / Q000601:surgery; D013392:Sucralfate / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects*
D011458:Prostaglandins E; D013392:Sucralfate; D004815:Epidermal Growth Factor; D011899:Ranitidine; D007213:Indomethacin